Pharma lobby claims economic benefit to society for expensive cancer drugsCancer patients on expensive new therapies can remain at work for longer, German pharma lobby vfa told Handelsblatt on Wednesday (p9) (APMHE 63973).
Bayer to acquire remaining BlueRock sharesBayer will acquire the remaining 59.8% of shares of cell therapy developer BlueRock Therapeutics from U.S. venture capital Versant, with whom Bayer co-founded BlueRock in 2016, FAZ reports on Friday (p21) (APMHE 63988).
Bayer sells stake in chemical park operatorBayer has sold its 60% stake in chemical park operator Currenta to Australian investment firm Macquarie for around €1.17 billion, Handelsblatt (p23) and FAZ (p19) wrote on Thursday (APMHE 63964).
Merck KGaA earnings rise thanks to increase in drug salesThe earnings of Merck KGaA rose 7% to €4 billion in the second quarter of 2019 thanks to a drug sales increase of €100 million to €1.7 billion, FAZ (p21, 22) and Handelsblatt (p21) report on Friday (APMHE 63981).
German biotechs post promising prospectsGerman biotechs MorphoSys, Evotec and Medigene posted promising developments for drug R&D and partnerships in their second-quarter results presentations, FAZ reported on Thursday (p25).
Novartis hit by data manipulation case on ZolgensmaNovartis faces huge risks in the data manipulation case on the gene therapy Zolgensma (onasemnogene abeparvovec), Handelsblatt (p20) FAZ (p22), SZ (p24) and Die Welt (p13) reported on Thursday and SZ on Friday (p15) (APMHE 63960).
Profitability gap in pharma widensThe profitability gap between research-based pharma companies and generic companies has widened according to 2019 first half results, Handelsblatt wrote on Wednesday (p20, 29).
DocMorris against German pharmacy billGerman pharmacy chain DocMorris will "exhaust all our legal possibilities" to block the country's "local pharmacies reinforcement" bill presented by Health Minister Jens Spahn, weekly Wirtschaftswoche reports on Friday (p23), FAZ (p20) and SZ (p16) reported on Monday.
Off-label use prescriptions on the rise in GermanyThe number of off-label drug prescriptions in Germany rose 12% during the last three years, mostly in oncology indications, according to the statutory payers' joint medical service (MDK), FAZ reported on Thursday (p3).
Ketamine acts fast in depressionGerman psychiatrists have started using intravenous ketamine off-label to provide a fast-acting treatment for their patients with therapy-resistant depression while Janssen's Spravato (eketamine) has not yet been approved in the EU, SZ reported on Saturday (p33).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.